Abstract
Early diagnosis, early isolation, and early treatment are efficient solutions to control the COVID-19 pandemic. To achieve the accurate early diagnosis of SARS-CoV-2, a multiplex detection strategy is required for the cross-validation to solve the problem of “false negative” of the existing gold standard assay. Here, we present a multicomponent nucleic acid assay platform for SARS-CoV-2 detection based on lanthanide nanoparticle (LnNP)-tagging strategy. For targeting SARS-CoV-2’s RNA fragments ORF1ab gene, RdRp gene, and E gene, three LnNP probes can be used simultaneously to identify three sites in one sample through elemental mass spectrometry detection with limits of detection of 1.2, 1.3, and 1.3 fmol, respectively. With the multisite cross-validation, we envision that this multiplex and sensitive detection platform may provide an effective strategy for SARS-CoV-2 fast screening with a high accuracy.
【초록키워드】 SARS-CoV-2, mass spectrometry, COVID-19 pandemic, Diagnosis, early diagnosis, nucleic acid, SARS-CoV-2 detection, early treatment, Isolation, gold, RdRP, multiplex, platform, False negative, ORF1ab gene, RdRp gene, Cross-validation, Limits of detection, gold standard, E gene, problem, limits, high accuracy, ORF1, probe, effective, lanthanide, identify, required, can be used, RNA fragment, multisite, 【제목키워드】 SARS-CoV-2, Strategy, acid,